Monday, August 24
HYDERABAD: Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit shelves in March next year.Novo's strategy emphasizes price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early. Both companies focused on aggressive outreach to doctors, heavier advertising about obesity, tie-ups with clinics, patient incentives and distribution deals with local drugmakers, according to doctors, analysts, medical representatives, patients and distributors who spoke to Reuters.Lilly has even teamed up in India with well-known Bollywood actors in a social media ad campaign about obesity.India, projected to have the world's second-largest overweight or obes
ET Intelligence Group: Shares of Mahindra & Mahindra Financial Services (MMFS), the largest financier of tractors, have surged 27% over the past three months, including a 13% gain over the past month. The ET NBFC index has gained 4% and 2.3% during the said periods respectively. A strong second-quarter performance boosted by robust traction in the auto financing business following a rate cut in the goods and services tax (GST) aided the stock's outperformance. The company reported 13% year-on-year growth in assets under management (AUM) and a healthy expansion in net interest margin (NIM) for the quarter, aided by a reduction in cost of funds. The momentum is likely to continue in the coming quarters. NIM improved to 7% in the September quarter from 6.5% a year ago, supported by highe
